

SciBX

Science-Business eXchange



FROM THE MAKERS OF

BioCentury[®] AND nature

Science-Business eXchange

From the makers of BioCentury and Nature: combining Business Intelligence + Scientific Acumen

If identifying innovative life science research from the 12,000 new scientific articles that are added to MEDLINE each week is a daunting task, deciding which discoveries have the potential to be translated into commercial products is an even more complex problem. As a result, significant time, effort and resources are devoted to searching for innovative, commercially relevant science and framing that work in the correct scientific and commercial context.

SciBX: Science-Business eXchange offers a unique solution

SciBX is a weekly publication that provides timely, concise and understandable analysis of the scientific content and commercial potential of the most important translational research papers from across the life science literature.

For corporate executives, business development specialists and investment professionals SciBX will:

- Save time and resources by identifying and describing emerging science and technology with commercial potential
- Facilitate early opportunities for investment, alliances and partnerships
- Identify novel competition

Over 16,000 articles were evaluated in 2008; less than 7% were selected for inclusion in SciBX

For academic and industry scientists SciBX will:

- Save time and resources by identifying and describing the key translational research papers
- Provide important scientific and commercial perspective on the key breakthroughs
- Improve understanding of the commercial goals and problem areas in translational research, and drug discovery and development obstacles

82% of selected articles are from outside the traditional gatekeeper publications

In 2008 SciBX highlighted research that impacted on more than:

630 marketed compounds

333 public biotechnology companies

430 academic institutions

341 private biotechnology companies

2,500 unique targets and compounds with commercial potential



INTRODUCING SciBX:

Overview	1
Inside SciBX	2
The SciBX Team	3
About BioCentury	4
About NPG	4



Filtering, analyzing and identifying new industry-shaping research for:

- Biopharma executives
- R&D managers
- Licensing specialists
- Research scientists
- Tech transfer officers
- Regulatory planners
- Venture capitalists
- Financial analysts
- Asset managers
- IP attorneys
- Consultants
- Knowledge centers



Inside SciBX

SciBX is published weekly as an HTML web site for institutional access and as a PDF delivered to individual subscribers by e-mail. Each issue contains a timely, comprehensive and understandable analysis of the most commercially promising new life science and technology.

Understanding the business context and commercial relevance of new science is the key to lowering investment risk and stimulating industry innovation.

The SciBX editorial team chooses from hundreds of scientific papers each week to distill the most important developments and presents this intelligence in two essential formats: Analysis and The Distillery.

Analysis — Provides an in-depth review of new research findings and an essential understanding of the commercial impact and next steps required to transform these developments into commercial value. Interviews with leading experts go beyond the basic science to analyze and identify these crucial next steps and the impact of these findings on players in the field.


The Analysis contains high-quality graphics and tables laying out the science and the competitive space and is organized to enable the reader to quickly find articles in the key areas of targets and mechanisms, markers, drug platforms, tools and the public-private interface.

The Distillery — Filters and classifies the most important current research papers in biotechnology, life science and chemistry and is also organized to enable the reader to quickly find articles of primary interest:

- This week in therapeutics includes important research on targets and compounds grouped by disease class and indication.
- This week in techniques focuses on novel findings relevant to research tools, disease models and manufacturing processes that have the potential to enable or improve drug discovery and development.

The Distillery goes beyond the abstract to explain the science, its commercial relevance, licensing status and companies known to be working in the area.

There is an urgent need to translate early stage research into new medicines and tools for drug discovery. SciBX will help academia, the biopharma industry and investors bridge this divide.



The SciBX Team

SciBX is a publishing collaboration between BioCentury Publications, Inc. and Nature Publishing Group that brings together the business intelligence of BioCentury and the scientific acumen of Nature Publishing Group.

A global team using established best practices.

SciBX is created by an experienced global team of researchers, analysts and writers, using the established best practices of both companies to identify and evaluate high-quality scientific research, conduct thorough industry-shaping reporting and analysis, informed by comprehensive in-house industry databases.

Editor-in-Chief

Karen Bernstein, Ph.D.

Karen is the internationally recognized Co-Founder, Chairman & Editor-in-Chief of BioCentury. She has been writing and publishing on biotechnology since 1987.

Executive Editors

Gaspar Taroncher-Oldenburg, Ph.D.

Gaspar was a scientific editor of Nature Biotechnology for five years and holds a Ph.D. from MIT.


Steve Edelson

Steve has been a writer, news editor and financial editor for BioCentury since 1998.

Editor

Tracey Baas, Ph.D.

Tracey serves as Associate Editor at NPG and has spent the past 12 years conducting research. She holds a Ph.D. from the University of Washington.



Market Research

Walter Yang

Walter, who holds a Masters of Finance and Accounting from the London School of Economics, has been a writer, research analyst and research director at BioCentury since 1999.

Writers

Tim Fulmer, Ph.D.

Tim, a Staff Writer at BioCentury, has 10 years of experience as a technical translator and writer and holds a Ph.D. in biochemistry from the University of Illinois.

Michael J. Haas

Mike, a Senior Writer at BioCentury, has 14 years of experience as an analytical chemist and mass spectrometry group leader at DuPont, DuPont Merck, DuPont Pharma and Bristol-Myers Squibb.

Lev Osherovich, Ph.D.

Lev is an Academic in Residence and Senior Writer at BioCentury. He holds a Ph.D. in biochemistry from the University of California, San Francisco. Lev joins the team during a sabbatical from a Burroughs Wellcome Fund fellowship.

Kai-Jye Lou

Kai-Jye, who serves as a Staff Writer at BioCentury, holds an M.S. in biomedical engineering and a B.S. in computational and systems biology from the University of California, Los Angeles.

Brian Moy

Brian, a Staff Writer at BioCentury, previously served as a Research Analyst for the company. He has a B.S. in Biological Sciences from the University of Notre Dame.


Lauren Martz

Lauren, a Staff Writer at BioCentury, previously served as a Research Analyst for the company. She holds a B.S.E. in bioengineering from the University of Pennsylvania.

Management

SciBX is published by BioCentury Publications, Inc. and Nature Publishing Group, under the direction of a Joint Steering Committee.

If your next strategic or investment decision depends on understanding the scientific and business context of cutting-edge science and technology, then you need a trusted source of information. BioCentury and Nature Publishing Group are the trusted authorities in our respective areas of expertise and together we are creating compelling new products and services that will bring added value in this space.



BioCentury®

BioCentury provides independent, informed
BUSINESS INTELLIGENCE

www.biocentury.com

BioCentury is recognized as the essential provider of independent, informed business intelligence that regularly affects decisions made by bioindustry leaders and investors throughout the world. BioCentury's mission is to provide value-added information and analysis for biotech and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of biopharmaceutical ventures.



Nature Publishing Group evaluates and identifies
HIGH-IMPACT SCIENCE

www.nature.com

The Nature Publishing Group has a long-established reputation as the preeminent publisher of high-impact science and analysis through its flagship title, Nature, and the discipline-specific Nature Research and Nature Reviews titles. The independent editorial teams and procedures that have been developed by Nature Publishing Group are renowned for quick, careful evaluation and identification of the originality and impact of each new development. The editorial processes and procedures have withstood the test of time, and their success can be gauged from the fact that although Nature-branded titles typically publish less than 10% of all the manuscripts submitted, they are consistently among the most-cited journals in their specific disciplines.

For more information on SciBX or to subscribe today, please visit Scibx.com

For institutional subscribers, SciBX is available as a full text html site via a site-wide license. Please contact your local NPG representative to secure your subscription, or to arrange a free site-wide trial

For individual and group subscribers, SciBX is available as a weekly PDF delivered direct to your e-mail account

Please contact BioCentury Subscriber Services on +1 650-595-5333

Scientific journals monitored by SciBX editorial team:

- The American Journal of Human Genetics
- Angewandte Chemie International Edition
- Blood
- Cancer Cell
- Cell
- Current Biology
- Developmental Cell
- The EMBO Journal
- Genes & Development
- Genome Research
- Immunity
- Journal of the American Chemical Society
- The Journal of Cell Biology
- The Journal of Clinical Investigation
- Journal of Clinical Oncology
- The Journal of Experimental Medicine
- Journal of Medicinal Chemistry
- Journal of the National Cancer Institute
- Molecular Cell
- Nano Letters
- Nature Biotechnology
- Nature Cell Biology
- Nature Chemical Biology
- Nature Genetics
- Nature Immunology
- Nature Materials
- Nature Medicine
- Nature Methods
- Nature Nanotechnology
- Nature Neuroscience
- Nature Structural & Molecular Biology
- Nature
- Neuron
- PLoS Biology
- Proceedings of the National Academy of Sciences of the United States of America
- Science